Changing what's possible

We separate tumor targeting from the payload, and rely on chemistry, not biology, for activation. This unprecedented flexibility can lead to greater activity and lower toxicity than has been previously possible.

CAPAC has been validated in the clinic and we are rapidly advancing novel therapies for patients with limited effective treatment options.

Latest News

November 4th - 7th

conference

Shasqi presenting two sessions at World ADC 2024

Shasqi VP of Research, Travis Biechele, PhD, and Founder and CEO, José Mejía Oneto, MD, PhD, will both be sharing data from Shasqi's CAPAC platform

‍

Travis Biechele will present "Understanding the drivers of target independent toxicities associated with ADCs and solutions to overcome them" on November 4^th at 10:30am PST.

José Mejía Oneto will present "Click Chemistry Enabled Pre-targeting as a Solution to Target-independent ADC Toxicities" on November 6^th at 12pm PST

The team will also be presenting two posters.

Learn more

‍

Targeting cancer with Click Chemistry

Less than 1% of administered drugs make it to their desired location in the body.

Next generation tumor-targeting

Our proprietary Click Activated Protodrugs Against Cancer (CAPAC^®) approach uses 2022 Nobel Prize-winning technology, click chemistry, to activate cancer therapies at the tumor.

We are the first company to use click chemistry in human patients.

CAPAC is modular

CAPAC is made up of two separate components that come together at the tumor.

Antigen-targeted activator

Binds to the tumor

Protodrugs

Cancer drugs that are inert until they click with the activator at the tumor

Activation

When the systemically administered protodrug reaches the targeting agent at the tumor, a click chemistry reaction takes place, activating the cancer drug.

Changing what's possible

Latest News

Together we can transform cancer treatment

Ready to help us develop the future of cancer therapies?

Interested in exploring a collaboration?

Targeting cancer with Click Chemistry

Less than 1% of administered drugs make it to their desired location in the body.

Next generation tumor-targeting

Our proprietary Click Activated Protodrugs Against Cancer (CAPAC®) approach uses 2022 Nobel Prize-winning technology, click chemistry, to activate cancer therapies at the tumor. We are the first company to use click chemistry in human patients.

CAPAC is modular

CAPAC is made up of two separate components that come together at the tumor.

Antigen-targeted activator

Binds to the tumor

Protodrugs

Cancer drugs that are inert until they click with the activator at the tumor

Activation

When the systemically administered protodrug reaches the targeting agent at the tumor, a click chemistry reaction takes place, activating the cancer drug.

Changing what's possible

Latest News

Together we can transform cancer treatment

Ready to help us develop the future of cancer therapies?

Interested in exploring a collaboration?

Our proprietary Click Activated Protodrugs Against Cancer (CAPAC^®) approach uses 2022 Nobel Prize-winning technology, click chemistry, to activate cancer therapies at the tumor.

We are the first company to use click chemistry in human patients.